Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Dine JL, Austin MK, Armer JM. Nursing education on lymphedema self-management and self-monitoring in a South African oncology clinic. J Cult Divers. 2011;18(4):126-8.